Wednesday, October 4, 2017
Mitochon Pharmaceuticals announced that it was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help develop its mitochondrial targeted compounds for treating Parkinson’s disease. The funding will go to pivotal animal studies to assess the benefits of Mitochon’s compounds in ameliorating the deficits associated with dopaminergic neuron loss, the hallmark of Parkinson’s disease. If successful, Mitochon’s compounds, MP101 ad MP201 could be in patients as early as 2019.